Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PEPD | P12955 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19192922 | 1.00 | LMNA (0.53) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL5491765 | 0.89 | LMNA (0.54) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL5491755 | 0.89 | LMNA (0.54) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL6882664 | 0.89 | LMNA (0.54) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL31159664 | 0.88 | LMNA (0.49) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL18796576 | 0.88 | LMNA (0.49) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL26199256 | 0.87 | LMNA (0.53) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL26199184 | 0.87 | LMNA (0.53) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL4179454 | 0.87 | FKBP1A (0.55) | LMNARAB9ASMN1; SMN2PKMFKBP1A | |
| SCHEMBL13662643 | 0.87 | FKBP1A (0.55) | LMNARAB9ASMN1; SMN2PKMFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014941-B2 | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | COCRYSTAL PHARMA, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200123177-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014941-B2 | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | ITPA, POLR2H, POLR2E | LMNA 4249/4885RAB9A 1737/4885SMN1; SMN2 2913/4885 |
| US-20200123177-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | ITPA, POLR2H, POLR2E | LMNA 4249/4885RAB9A 1737/4885SMN1; SMN2 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.